Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

Patient-specific precision medicine approaches are important for future cancer therapies. Here, the authors show that functional drug profiling with Rhabdomyosarcoma cells isolated from PDX and primary patient tumors uncovers patient-specific vulnerabilities.

Guardado en:
Detalles Bibliográficos
Autores principales: Gabriele Manzella, Leonie D. Schreck, Willemijn B. Breunis, Jan Molenaar, Hans Merks, Frederic G. Barr, Wenyue Sun, Michaela Römmele, Luduo Zhang, Joelle Tchinda, Quy A. Ngo, Peter Bode, Olivier Delattre, Didier Surdez, Bharat Rekhi, Felix K. Niggli, Beat W. Schäfer, Marco Wachtel
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Q
Acceso en línea:https://doaj.org/article/e1a776112ff34407a13275f886ecd3a9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!